Beijing Med-Pharm Corporation has named pharmaceutical executive Ms Yanping Zhao to the new post of Corporate Vice President.
Serving as the chief representative for Beijing Med-Pharm in China, Ms Zhao will work with Mr David Gao, CEO of Beijing Med-Pharm, to oversee and coordinate all the company's Chinese subsidiaries. She will also have responsibility for corporate strategic business development, including mergers and acquisitions, and corporate functions in China.
“We are very pleased to have an executive of Ms Zhao's caliber join our management team,” said Mr Gao. “With an outstanding track record in operations and business development, she is very well respected in the pharmaceutical industry in China.”
“Beijing Med-Pharm has a first-mover advantage in controlling important distribution channels and executing a unique business model that delivers both demand creation and fulfillment,” said Ms Zhao. “This is a new way of structuring a pharmaceutical enterprise in China and I am eager to apply my expertise to continuing its growth in this dynamic market.”
Ms Zhao joins Beijing Med-Pharm from China Biopharmaceutical Limited, a Hong Kong Exchange-listed company, where she served as Vice President, Executive Director and Chief Representative of the Beijing Office. While at China Biopharmaceutical in 2005, Ms Zhao was instrumental in establishing, developing and selling 55 percent of Shandong China Tai Freda Pharmaceutical to Bausch & Lomb for $200 million, which at the time was the largest pharmaceutical merger and acquisition ever in China.
She has also held senior management posts at Hainan Tiger Lily Pharmaceutical, including General Manager and head of Research and Development, Shandong Chia Tai Freda Pharmaceutical, Xian Chia Tai Pharmaceutical, Ankang Chia Tai Pharmaceutical, and Nei Menggu Yuanbaoshan Pharmaceutical. She began her industry career at the China Nei Mengu Autonomous Region Medicine and Health Products Import & Export Corporation, ultimately serving as Director. Ms Zhao holds a degree from Shenyang Pharmaceutical University and an MBA from Dalian University of Technology.